Alto Neuroscience Shifts Focus After Mixed ALTO-101 Data
Event summary
- ALTO-101 failed to achieve statistical significance in Phase 2 trial for cognitive impairment associated with schizophrenia (CIAS).
- Subgroup analysis showed nominally significant effects on theta-ITC measure in more cognitively impaired patients.
- Company developed modified-release formulation of ALTO-101 and will explore partnering opportunities.
- ALTO-207 Phase 2b trial for treatment-resistant depression expected to begin in first half of 2026.
The big picture
Alto Neuroscience's decision to deprioritize ALTO-101 reflects the challenges of developing precision medicines for complex neuropsychiatric conditions. The company's strong cash position ($275 million) and focus on ALTO-207, which targets a significant unmet need in treatment-resistant depression, positions it competitively in the psychiatric drug development space. The outcome of ALTO-101 highlights the importance of subgroup analyses in neuropsychiatric trials, where heterogeneous patient populations can obscure overall effects.
What we're watching
- Pipeline Prioritization
- How Alto's shift in focus from ALTO-101 to ALTO-207 will impact its development timeline and resource allocation.
- Partnering Strategy
- Whether the modified-release formulation of ALTO-101 can attract strategic partners despite mixed Phase 2 results.
- Clinical Validation
- The pace at which ALTO-207 can demonstrate efficacy in treatment-resistant depression, given its strong prior clinical data.